SYS6002 + JMT101 + enlonstobart

This combination consists of three distinct investigational and recently approved anti-cancer biologic drugs: - **SYS6002 (CRB-701):** A next-generation antibody-drug conjugate (ADC) targeting Nectin-4, designed using third-generation conjugation technology for improved stability, reduced systemic toxicity, and enhanced intra-tumoral drug release. SYS6002 utilizes a site-specific cleavable linker loaded with MMAE, with demonstrated efficacy and tolerability in advanced solid tumors including metastatic urothelial carcinoma and cervical cancer[1][4][7]. - **JMT101:** A fully human monoclonal IgG1 antibody that targets epidermal growth factor receptor (EGFR), preventing ligand-induced activation and downstream signaling. It exhibits efficacy alone and in combination (notably with chemotherapy or EGFR TKIs) in advanced solid tumors, especially those with wild-type RAS/non-BRAF V600E mutations, and antagonizes EGFR-mediated cell proliferation[2][5][8]. - **Enlonstobart (Enshuxing):** A recombinant, fully humanized immunoglobulin G4 monoclonal antibody targeting programmed cell death protein 1 (PD-1), developed as an immune checkpoint inhibitor with approved use in recurrent/metastatic PD-L1-positive cervical cancer. It is under development for broader solid tumor indications and works by blocking PD-1 receptor, enabling the reactivation of anti-tumor T-cell activity[3][6]. Together, this *triplet regimen* combines a Nectin-4-targeted cytotoxic payload, EGFR signaling blockade, and immune checkpoint inhibition—potentially aiming for enhanced tumor cell killing, prevention of growth signaling escape, and immune system-mediated tumor eradication.

Brand names

Enshuxing

Other names

SYS6002SYS-6002SYS 6002CRB-701CRB701CRB 701JMT101JMT-101JMT 101enlonstobartEnshuxing